A Center on Alpha-Synuclein Strains in Alzheimer's Disease and Related Disorders
PI: John Q. Trojanowski, MD, PhD
The goals of this Penn U19 “Center On Alpha-synuclein Strains In Alzheimer Disease & Related Dementias” at the University of Pennsylvania (Penn) Perelman School of Medicine (PSOM) are to elucidate mechanisms of progressive neurodegeneration and dementia in AD +alpha-Synuclein (AD+aSyn), Parkinson’s disease (PD), Parkinson’s disease with dementia (PDD), dementia with lewy bodies (DLB), and multiple system atrophy (MSA).
We hypothesize that cellular dysfunction and death result from transmission of distinct pathologic aSyn strains leading to toxic LBS and neurites (LNs) in AD+aSyn and LBD. We contrast these aSyn strains with those forming glial cytoplasmic inclusions (GCIs) in MSA that rarely associate with dementia or AD pathology as control aSyn strains in our studies. Further, aSyn strain diversity leads to heterogeneity in AD+aSyn and LBD.
DATA SHARING AND TRAINING
This NIA funded U19 includes a unique resource component allowing other investigators interested in research on amyloid polymorphisms to make use of procedures we developed over the past 20 years to share biologicals obtained through this U19 Center an from prior collections of CSF, plasma, serum, DNA/RNA and brain samples from Alzheimer’s disease (AD) and Lewy body (LB) disease (LBD) patients who have been followed through NIH-funded programs. More information on our data sharing and training opportunities is available on our Resources page.